Somatuline depot and Zolpidem drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Somatuline depot and Zolpidem. Common interactions include hospitalisation among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people who take Somatuline depot and Zolpidem have. It is created by eHealthMe based on reports of 10 people who take Somatuline depot and Zolpidem from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 24, 2022

10 people who take Somatuline depot and Zolpidem together, and have interactions are studied.


What is Somatuline depot?

Somatuline depot has active ingredients of lanreotide acetate. It is often used in acromegaly. eHealthMe is studying from 4,024 Somatuline depot users for its effectiveness, alternative drugs and more.

What is Zolpidem?

Zolpidem has active ingredients of zolpidem tartrate. It is often used in insomnia. eHealthMe is studying from 82,927 Zolpidem users for its effectiveness, alternative drugs and more.

Number of Somatuline depot and Zolpidem reports submitted per year:

Somatuline depot and Zolpidem drug interactions.

Common Somatuline Depot and Zolpidem drug interactions by gender *:

female:

  1. Hospitalisation
  2. Upper limb fracture
  3. Weight decreased
  4. Abdominal distension
  5. Flatulence
  6. Hyperhidrosis
  7. Injection site mass
  8. Injection site pain
  9. Ligament pain
  10. Pneumonia

male:

  1. Diarrhoea

Common Somatuline Depot and Zolpidem drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Alopecia
  2. Upper limb fracture
  3. Weight decreased
  4. Anaemia
  5. Adrenal insufficiency
  6. Amnesia
  7. Blood sodium decreased
  8. Death
  9. Hospitalisation
  10. Lower limb fracture

60+:

  1. Diarrhoea

Common conditions people have *:

  1. Carcinoid Syndrome (syndrome includes flushing and diarrhoea, and, less frequently, heart failure and bronchoconstriction): 2 people, 20.00%
  2. Pain: 1 person, 10.00%
  3. Neuroendocrine Tumor: 1 person, 10.00%
  4. Metastatic Carcinoid Tumor: 1 person, 10.00%
  5. Hypothalamo-Pituitary Disorder (loss of function in an endocrine gland due to failure of the pituitary gland to secrete hormones which stimulate that gland's function): 1 person, 10.00%
  6. Gastrointestinal Inflammation (inflammation of stomach and intestine): 1 person, 10.00%
  7. Diabetes: 1 person, 10.00%
  8. Depression: 1 person, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Somatuline depot and Zolpidem?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Somatuline depot and Zolpidem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Somatuline depot interactions:

Browse all interactions between Somatuline depot and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Zolpidem interactions:

Browse all interactions between Zolpidem and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on lanreotide acetate and zolpidem tartrate (the active ingredients of Somatuline depot and Zolpidem, respectively), and Somatuline depot and Zolpidem (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Somatuline depot and Zolpidem.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: